NCT03004417View on ClinicalTrials.gov

Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions

COPD

Interventions

DRUG

CHF 6001 Dose1

CHF 6001 plus placebo

DRUG

CHF 6001 Dose2

CHF 6001 only (high dose)

OTHER

Placebo

Placebo only

Trial Locations (1)

M23 9QZ

Medicines Evaluation Unit Ltd, Manchester

All Listed Sponsors

collaborator

SGS S.A.

INDUSTRY

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT03004417 - Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD | Biotech Hunter | Biotech Hunter